SEC Form SC 13G/A filed by Kezar Life Sciences Inc. (Amendment)
$KZR
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/11/2023 | $4.00 | Overweight → Equal Weight | Wells Fargo |
3/16/2023 | Outperform → Mkt Perform | William Blair | |
12/8/2021 | $19.00 | Overweight | Wells Fargo |
11/16/2021 | $12.00 → $20.00 | Buy | HC Wainwright & Co. |
7/20/2021 | $14.00 | Buy | JonesTrading |
Wells Fargo downgraded Kezar Life Sciences from Overweight to Equal Weight and set a new price target of $4.00
William Blair downgraded Kezar Life Sciences from Outperform to Mkt Perform
Wells Fargo initiated coverage of Kezar Life Sciences with a rating of Overweight and set a new price target of $19.00